Patient Safety Technologies Reports Second Quart...(------ -- Total li...),Health

Date:8/6/2009

------ -- Total liabilities and stockholders' equity $7,808 $7,914 ====== ====== * Derived from audited financial statements for year ended December 31, 2008 PATIENT SAFETY TECHNOLOGIES, INC. CONSOLIDATED STATEMENT OF OPERATIONS (In thousands, except per share data) (unaudited) For the Six For the Quarter Months Ending Ending June 30, June 30, 2009 2008 2009 2008 ---- ---- ---- ---- Revenues $1,028 $557 $1,964 $1,057 Cost of revenue 619 326 1,168 719 --- --- ----- --- Gross profit 409 231 796 338 Operating expenses: Research and development 86 38 199 81 Sales and marketing 553 682 1,202 1,134 General and administrative 1,361 1,687 2,616 2,723 ----- ----- ----- ----- Total operating expenses 2,000 2,407 4,017 3,938 ----- ----- ----- ----- Operating loss (1,591) (2,176) (3,221) (3,600) Other income (expenses): Interest expense (220) (88) (440) (175) Change in fair value of warrant liability (2,155) (168) (3,867) (16
'/>"/>

SOURCE Patient Safety Technologies, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. California Cancer Specialists Medical Group, Inc. Opens Outpatient Cancer Center in South Pasadena, Calif., With Renowned Medical Staff, State-of-the-Art Technology
2. Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs)
3. Inpatient Management, Inc. and Reid Hospital Achieve Performance Improvement and Cost Savings
4. Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer
5. Genome of Leukemia Patient Reveals Common Mutations
6. Digital mammography plus digital breast tomosynthesis may decrease patient recall rates
7. Happy Employees Lead to Healthier Patients
8. Londons Barts Hospital Selects Varian Equipment to Offer Advanced Radiotherapy to More Cancer Patients
9. Lilly Broadens Income Eligibility for Patient Assistance Programs
10. Surveyed Physicians Will Treat Over 50 Percent of Hepatitis C Genotype 1-Infected Patients With the Protease Inhibitor Telaprevir
11. Lexicon Initiates Phase 2 Clinical Trial of LX2931 in Patients With Rheumatoid Arthritis